Mark‐David Levin
Impact in
- Hematology top 0.5%
- Multiple Myeloma Research and Treatments
- Genetics top 0.5%
- Chronic Lymphocytic Leukemia Research
Papers in
- Genetics 82
- Chronic Lymphocytic Leukemia Research 76
- Hematology 66
- Multiple Myeloma Research and Treatments 40
- Chronic Myeloid Leukemia Treatments 11
- Co-authors
- Agnes Jager (9 shared papers)Hánah N. Rier (11 shared papers)Stefan Sleijfer (5 shared papers)Joost van Rosmalen (12 shared papers)Arnon Philip Kater (31 shared papers)Andrea Britta Maier (1 shared paper)Marc C. J. M. Kock (4 shared papers)Peter E. Westerweel (19 shared papers)
- Journals
- Blood (25 papers)HemaSphere (13 papers)Blood Advances (8 papers)Blood Cancer Journal (8 papers)British Journal of Haematology (7 papers)
- Partner nations
- NetherlandsUnited StatesDenmark
In The Last Decade
Mark‐David Levin
161 papers receiving 4.7k citations
Mark‐David Levin's Hit Papers
Peers
Comparison fields: 5 of 104
- Hematology 2.3k
- Genetics 1.5k
- Oncology 1.5k
- Pathology and Forensic Medicine 676
- Immunology 642
Countries citing papers authored by Mark‐David Levin
This map shows the geographic impact of Mark‐David Levin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark‐David Levin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark‐David Levin more than expected).
Fields of papers citing papers by Mark‐David Levin
This network shows the impact of papers produced by Mark‐David Levin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark‐David Levin. The network helps show where Mark‐David Levin may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark‐David Levin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 167 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study Hit paper breakdown → | 2019 | 769 |
| 2 | Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study Hit paper breakdown → | 2020 | 295 |
| 3 | 2020 | 216 | |
| 4 | First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia Hit paper breakdown → | 2023 | 201 |
| 5 | 2018 | 195 | |
| 6 | 2016 | 177 | |
| 7 | Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities Hit paper breakdown → | 2022 | 165 |
| 8 | 2019 | 158 | |
| 9 | 2021 | 139 | |
| 10 | 2016 | 133 | |
| 11 | 2016 | 102 | |
| 12 | 2023 | 92 | |
| 13 | 2022 | 92 | |
| 14 | 2019 | 91 | |
| 15 | 2021 | 75 | |
| 16 | Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial Hit paper breakdown → | 2024 | 72 |
| 17 | 2024 | 51 | |
| 18 | 2016 | 50 | |
| 19 | 2022 | 50 | |
| 20 | 2019 | 49 |
About Mark‐David Levin
Mark‐David Levin is a scholar working on Genetics, Hematology, Pathology and Forensic Medicine, Oncology and Immunology, having authored 167 papers that have together received 4.8k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (76 papers), Multiple Myeloma Research and Treatments (40 papers), Lymphoma Diagnosis and Treatment (40 papers), Immunodeficiency and Autoimmune Disorders (14 papers), Protein Degradation and Inhibitors (11 papers), Chronic Myeloid Leukemia Treatments (11 papers), Peptidase Inhibition and Analysis (10 papers) and Cancer Treatment and Pharmacology (9 papers). The work is most often cited by research in Hematology (2.3k citations), Genetics (1.5k citations), Oncology (1.5k citations), Pathology and Forensic Medicine (676 citations) and Immunology (642 citations). Mark‐David Levin has collaborated with scholars based in Netherlands, United States and Denmark. Frequent co-authors include Agnes Jager, Hánah N. Rier, Stefan Sleijfer, Joost van Rosmalen, Arnon Philip Kater, Andrea Britta Maier, Marc C. J. M. Kock, Peter E. Westerweel, Sanne H. Tonino and Tom Hofland. Their work appears in journals such as Blood, HemaSphere, Blood Advances, Blood Cancer Journal and British Journal of Haematology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.